DAX	12.583	+0,66%	DB-Dow	24.282	-0,23%
TecDAX	2.635	+0,69%	Dollarkurs	1,207	-0,30%

Apricus Biosciences News


0,204 €		-10,53%	-0,024 €

10:02 Uhr Stuttgart | Mehr Kurse »

WKN: A2AT45

ISIN: US03832V3078

US-Symbol: APRI

Typ: Aktie

Kaufen

+ Depot

Apricus Biosciences News

1 2 3 Weiter

16.04.18	Apricus Biosciences Announces Outcome of Vitaros(TM) End-of-Review Meeting with FDA	GlobeNewswire
28.03.18	Apricus Biosciences Announces Pricing of $3.55 Million Public Offering	GlobeNewswire
27.03.18	Apricus Biosciences Announces Proposed Public Offering	GlobeNewswire
26.03.18	Apricus Biosciences Announces Scheduling of Vitaros(TM) End-of-Review Meeting with FDA	GlobeNewswire

01.03.18	Apricus Biosciences, Inc. : Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2017 Financial Results	GlobeNewswire
21.02.18	Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2017 Financial Results Conference Call	GlobeNewswire
16.02.18	Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros(TM)	GlobeNewswire
26.10.17	Apricus Biosciences Announces Corporate Update and Third Quarter 2017 Financial Results Conference Call	GlobeNewswire
10.10.17	Apricus Biosciences to Present at the 2017 BIO Investor Forum	GlobeNewswire
11.09.17	Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market	GlobeNewswire
05.09.17	Apricus Biosciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference	GlobeNewswire
31.08.17	Apricus Biosciences Announces FDA Acknowledgement of Vitaros(TM) Class 2 NDA Resubmission	GlobeNewswire
29.08.17	Apricus Biosciences Files NDA Resubmission for Vitaros(TM)	GlobeNewswire
02.08.17	Apricus Biosciences Provides Corporate Update and Second Quarter 2017 Financial Results	GlobeNewswire
26.07.17	Apricus Biosciences Announces Corporate Update and Second Quarter 2017 Financial Results Conference Call	GlobeNewswire
11.05.17	Apricus Biosciences Provides Corporate Update and First Quarter 2017 Financial Results	GlobeNewswire
04.05.17	Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study	GlobeNewswire
04.05.17	Apricus Biosciences Announces Corporate Update and First Quarter 2017 Financial Results Conference Call	GlobeNewswire
02.05.17	Apricus Biosciences Regains Compliance with Nasdaq Continued Listing Requirements	GlobeNewswire
21.04.17	Apricus Biosciences Announces Pricing of $7.0 Million Public Offering	GlobeNewswire
13.03.17	Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results	GlobeNewswire
09.03.17	Apricus Biosciences Announces Corporate Update, Fourth Quarter and Full Year 2016 Financial Results Conference Call	GlobeNewswire
08.03.17	Apricus Biosciences Announces Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals	GlobeNewswire
09.02.17	Apricus Biosciences Receives Positive Nasdaq Listing Determination	GlobeNewswire
08.02.17	Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference	GlobeNewswire
18.01.17	Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Mexico	GlobeNewswire
03.01.17	Apricus Biosciences Promotes Mary Naggs to Vice President, General Counsel	GlobeNewswire
27.12.16	Apricus Biosciences Announces the Launch of Vitaros® for the Treatment of Erectile Dysfunction in Lebanon by Elis Pharmaceuticals	GlobeNewswire
01.12.16	Apricus Biosciences Receives Nasdaq Compliance Notice	GlobeNewswire
29.11.16	Apricus Biosciences to Present at the 9th Annual LD Micro Main Event	GlobeNewswire
18.11.16	Apricus Biosciences Provides Update on Vitaros NDA Following Receipt of FDA Feedback	GlobeNewswire
20.10.16	Apricus Biosciences Announces 1-for-10 Reverse Stock Split	GlobeNewswire
20.10.16	Apricus Biosciences Announces 1-for-10 Reverse Stock Split	GlobeNewswire
12.10.16	Apricus Biosciences to Present at the 2016 BIO Investor Forum	GlobeNewswire
29.09.16	Apricus Biosciences Closes $3.7 Million Registered Direct Offering	GlobeNewswire
23.09.16	Apricus Biosciences Announces $4.6 Million Registered Direct Offering	GlobeNewswire
21.09.16	Apricus Biosciences Announces the Launch of Vitaros® in the Czech Republic and Slovakia by Recordati	GlobeNewswire
20.09.16	Apricus Biosciences Announces Completion of Transfer of the Marketing Authorizations for Vitaros® in Finland and Denmark to Ferring Pharmaceuticals	GlobeNewswire
08.09.16	Apricus Biosciences Announces Approval of Vitaros® for the Treatment of Erectile Dysfunction in Argentina	GlobeNewswire
07.09.16	Apricus Biosciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference	GlobeNewswire
06.09.16	Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Portugal, Ireland and Poland by Recordati	GlobeNewswire
15.08.16	Apricus Biosciences Announces Completion of Transfer of the United Kingdom Marketing Authorization for Vitaros® to Ferring Pharmaceuticals	GlobeNewswire
10.08.16	Apricus Biosciences Announces Completion of Transfer of Vitaros® German Marketing Authorization to Ferring Pharmaceuticals	GlobeNewswire
04.08.16	Apricus Biosciences Provides Corporate Update and Second Quarter Financial Results	GlobeNewswire
04.08.16	Apricus Biosciences to Present at the Canaccord Genuity 36th Annual Growth Conference	GlobeNewswire
01.08.16	Apricus Biosciences Announces Corporate Update and Second Quarter 2016 Financial Results Conference Call	GlobeNewswire
27.07.16	Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Lebanon	GlobeNewswire
25.07.16	Apricus Biosciences, Inc. : Apricus Biosciences Further Expands Existing Vitaros® Partnership with Ferring Pharmaceuticals in Europe and Asia	GlobeNewswire
06.07.16	Apricus Biosciences Enters Into Common Stock Purchase Agreement With Aspire Capital	GlobeNewswire
09.05.16	Apricus Biosciences Provides Corporate Update and First Quarter Financial Results	GlobeNewswire